Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.... (14407 12109 53722 47802 ....)

HOME >> BIOLOGY >> TECHNOLOGY

Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007

Date:2/20/2008

14,407 12,109 53,722 47,802

Marketing, selling and

general and administrative 11,696 10,771 44,801 40,627

Research and development 1,965 1,321 5,658 4,828

13,661 12,092 50,459 45,455

Operating income 746 17 3,263 2,347

Interest expense, net (129) (176) (588) (914)

Other 185 57 (1) 416

Income (loss) before income

taxes 802 (102) 2,674 1,849

Income tax provision (benefit) (4) (163) 57 (58)

Net Income $ 806 $ 61 $ 2,617 $ 1,907

Earnings per share:

Basic $ .05 $ - $ .15 $ .11

Diluted $ .04 $ - $ .15 $ .11

Shares used in computing

earnings per share:

Basic 17,666,940 17,347,880 17,538,254 17,298,352

Diluted 18,093,058 17,542,228 17,926,384 17,399,719

CONSOLIDATED SEGMENT REVENUE DETAIL

(dollars in thousands)

Three Months Year Ended

Ended December 31, December 31,

2007 2006 2007 2006

DBM $ 17,107 $ 14,792 $ 65,794 $ 57,493

Hybrid/Synthetic 591 332 1,760 1,270

Core Revenue 17,698 15,124 67,554 58,763

Traditional Tissue 4,491 4,674 17,623 16,955

Spinal Allografts 2,438 3,027 10,739 13,795

Client Services 2,085
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6
Related biology technology :

1. Osteotech Announces Fourth Quarter and Full Year Earnings Release and Conference Call Schedule
2. Osteotech to Present at Sidoti Conference in San Francisco
3. Osteotech to Present at Roth Capital Partners 2007 New York Investor Conference
4. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
5. Amsterdam Molecular Therapeutics Reports Full Year Results 2007
6. Medivation Reports Year-End 2007 Financial Results and Pipeline Progress
7. United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results
8. Favrille Reports Fourth Quarter and Year End 2007 Financial Results
9. JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis
10. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Feasible in Acute Myocardial Infarction Patients, American Heart Journal Paper Reports
11. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results

Post Your Comments:

Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $....(14407 12109 53722 47802 ....)